Wegovy and Fatty Liver Disease — The Complete Australian Guide

Both Wegovy and Ozempic contain semaglutide — the same active ingredient. The difference is the dose. Ozempic is dosed at up to 1mg weekly and is TGA-approved in Australia for the management of type 2 diabetes. Wegovy is dosed at 2.4mg weekly — more than double — and is TGA-approved for chronic weight management in adults with obesity, and now for MASH with moderate to advanced fibrosis.

The practical implication is that a patient with type 2 diabetes taking Ozempic is on a lower dose of the same drug that has been shown to resolve MASH in nearly two-thirds of patients. The liver benefits of semaglutide are dose-dependent — the higher the dose, the more significant the hepatic effect.

The TGA's provisional approval is based on the ESSENCE trial — a phase 3, randomised, controlled clinical trial published in the New England Journal of Medicine on 30 April 2025, involving 800 patients across 37 countries over 72 weeks.

The trial enrolled adults with biopsy-confirmed MASH and liver fibrosis stages F2 or F3 (moderate to advanced fibrosis, one to two stages short of cirrhosis). Participants received either semaglutide 2.4mg weekly or a placebo injection.

The results at 72 weeks were striking across both primary endpoints:

Primary endpoint 1 — MASH resolution without worsening of fibrosis: 62.9% of patients in the semaglutide group achieved this, compared to 34.3% in the placebo group.

Primary endpoint 2 — Improvement in fibrosis by at least one stage without worsening of MASH: 37.0% of semaglutide patients achieved this, compared to 22.4% in the placebo group.

These are clinically meaningful differences. The trial demonstrated that semaglutide does not merely halt progression — it can actively reverse established liver fibrosis in many patients.

Importantly, the improvements in liver histology were not fully explained by weight loss alone. Even after adjusting for the degree of weight reduction, semaglutide showed superior liver outcomes compared to what weight loss alone would predict, suggesting a direct hepatic mechanism of action — likely through GLP-1 receptors expressed on liver sinusoidal endothelial cells.

On approximately 1 April 2026, the TGA granted provisional approval for Wegovy for the following indication:

Treatment of adults with non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with fibrosis stages F2 to F3).

The approval is provisional — meaning it requires further confirmatory data from the ongoing ESSENCE trial, which has a longer follow-up period assessing outcomes including liver transplantation, cirrhosis, and liver-related mortality. The TGA has required Novo Nordisk to provide this confirmatory data.

Professor Jacob George, who led the Australian arm of the study underpinning the TGA decision, noted that MASH is too often diagnosed after significant damage has occurred. The approval provides, for the first time, a pharmacological tool to treat the disease before it reaches irreversible stages.

Who qualifies under the approval:

• Adults with biopsy-confirmed or elastography-confirmed MASH
• Liver fibrosis at stage F2 or F3 (moderate to advanced)
• Non-cirrhotic (not yet at F4 cirrhosis)
• Must be prescribed by or in consultation with a hepatologist or gastroenterologist

The approval does not extend to patients with simple MASLD (fat accumulation without inflammation) or cirrhosis (F4 fibrosis). Patients with cirrhosis taking semaglutide for another approved indication should be monitored carefully.

If you are currently taking Wegovy for weight management, you may also be gaining liver benefits — even if you were not prescribed it for MASH.

MASLD affects approximately 30% of adults in Australia. Most people who have it do not know. Given the significant overlap between the population taking Wegovy for weight management and the population at risk of MASLD, there is a real possibility that a meaningful proportion of Australians on Wegovy have significant liver disease that is being treated without their knowing it — or that is improving silently alongside their weight loss.

This is not a reason for complacency. It is a reason to know your liver health status. If you have not had a FIB-4 score calculated, discuss it with your GP. If your FIB-4 score is in the indeterminate range, liver elastography will tell you whether your liver has fibrosis that warrants monitoring or treatment.

For patients taking Wegovy for weight management, monitoring of liver health is not yet formally mandated by Australian guidelines beyond the standard MASLD screening pathway. However, the clinical picture emerging from the ESSENCE trial and the updated AASLD guidance suggests the following is reasonable practice:

Before starting Wegovy: Full liver function panel including ALT, AST, GGT, alkaline phosphatase, and bilirubin, plus platelets. FIB-4 calculation from these results.

At 3 months: Repeat ALT and AST to assess for any transient enzyme changes during the weight loss phase.

At 12 months: Repeat FIB-4. If the score was previously indeterminate, consider repeat liver elastography to assess whether fibrosis has improved.

Ongoing: Annual liver function panel. If liver stiffness was elevated at baseline, liver elastography every 1–2 years.

The most practical first step is a FIB-4 score from a routine blood test. You do not need to fast specifically for liver function tests — they are part of a standard metabolic panel.

If your FIB-4 is in the indeterminate range (1.3–2.67), the next step is liver elastography. This is a non-invasive, 10–15 minute scan that measures liver stiffness (a proxy for fibrosis) and liver fat content (CAP score). It requires no hospitalisation, no injection, no radiation, and — at a growing number of Australian clinics — no GP referral.

Find a liver elastography clinic near you →

Wegovy received a positive recommendation from the Pharmaceutical Benefits Advisory Committee for a narrow group of very high-risk patients, but broad PBS subsidy for obesity is still under negotiation at the time of publication. For most Australians, Wegovy remains a private prescription, typically costing several hundred dollars per month.

For patients prescribed Wegovy specifically for MASH under the new TGA indication, the PBS pathway is different and currently evolving. Discuss the current subsidy status with your prescribing specialist.